These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 24266696)

  • 21. Avoiding ovarian hyperstimulation syndrome with the use of gonadotropin-releasing hormone agonist trigger.
    Fatemi HM; Garcia-Velasco J
    Fertil Steril; 2015 Apr; 103(4):870-3. PubMed ID: 25724740
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dual trigger with combination of gonadotropin-releasing hormone agonist and human chorionic gonadotropin significantly improves the live-birth rate for normal responders in GnRH-antagonist cycles.
    Lin MH; Wu FS; Lee RK; Li SH; Lin SY; Hwu YM
    Fertil Steril; 2013 Nov; 100(5):1296-302. PubMed ID: 23993928
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intensified ovarian stimulation in a GnRH antagonist protocol with agonist triggering: a prospective, clinical feasibility study.
    Griesinger G; Berndt H; Schultz L; Schultze-Mosgau A; Diedrich K; von Otte S
    Reprod Biomed Online; 2011 Feb; 22(2):133-9. PubMed ID: 21227753
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is the type of gonadotropin-releasing hormone suppression protocol for ovarian hyperstimulation associated with ectopic pregnancy in fresh autologous cycles for in vitro fertilization?
    Londra L; Moreau C; Strobino D; Bhasin A; Zhao Y
    Fertil Steril; 2016 Sep; 106(3):666-72. PubMed ID: 27320035
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rescue hCG to treat empty follicle syndrome after the use of a GnRH agonist as oocyte maturation trigger: First report on fresh embryo transfer and clinical pregnancy.
    Christopoulos G; Vlismas A; Barsoum-Derias E; El-Shawarby S; Trew G; Lavery S
    Hum Fertil (Camb); 2015; 18(4):248-52. PubMed ID: 26400626
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Research on the protocol of limited ovarian stimulation to prevent ovarian hyperstimulation syndrome].
    Zhu YM; Gao HJ; He RH; Huang HF
    Zhonghua Fu Chan Ke Za Zhi; 2006 Nov; 41(11):740-4. PubMed ID: 17327030
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Comparison of the efficiency between in-vitro maturation and in-vitro fertilization after early follicular phase GnRH agonist down-regulation in infertile women with polycystic ovary syndrome].
    Zhu RR; Xiao SQ; Zhao JZ; Lin J; Wang PY; Jin CC; Jin WM
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):833-7. PubMed ID: 24444560
    [TBL] [Abstract][Full Text] [Related]  

  • 28. GnRH antagonist rescue protocol combined with cabergoline versus cabergoline alone in the prevention of ovarian hyperstimulation syndrome: a randomized controlled trial.
    Fouda UM; Sayed AM; Elshaer HS; Hammad BE; Shaban MM; Elsetohy KA; Youssef MA
    J Ovarian Res; 2016 May; 9(1):29. PubMed ID: 27184139
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gonadotropin-Releasing Hormone-Agonist Triggering and a Freeze-All Approach: The Final Step in Eliminating Ovarian Hyperstimulation Syndrome?
    Davenport MJ; Vollenhoven B; Talmor AJ
    Obstet Gynecol Surv; 2017 May; 72(5):296-308. PubMed ID: 28558117
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Effect of domestic highly purified urinary follicle stimulating hormone on outcomes of in vitro fertilization-embryo transfer in controlled ovarian stimulation].
    Ye H; Huang GN; Cao YX; Zhong Y; Huang YH; Zhu GJ; Zhou LM; Chen ZJ; Shi JZ; Zeng Y; Weng N; Huang XF; Yang J; Zhu YM; Li YP; Yi D; Zhuang GL
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):838-42. PubMed ID: 24444561
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New algorithm for OHSS prevention.
    Papanikolaou EG; Humaidan P; Polyzos N; Kalantaridou S; Kol S; Benadiva C; Tournaye H; Tarlatzis B
    Reprod Biol Endocrinol; 2011 Nov; 9():147. PubMed ID: 22054506
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cycles triggered with GnRH agonist: exploring low-dose HCG for luteal support.
    Castillo JC; Dolz M; Bienvenido E; Abad L; Casañ EM; Bonilla-Musoles F
    Reprod Biomed Online; 2010 Feb; 20(2):175-81. PubMed ID: 20113955
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The gonadotropin-releasing hormone antagonist protocol--the protocol of choice for the polycystic ovary syndrome patient undergoing controlled ovarian stimulation.
    Kol S; Homburg R; Alsbjerg B; Humaidan P
    Acta Obstet Gynecol Scand; 2012 Jun; 91(6):643-7. PubMed ID: 22428986
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gonadotrophin-releasing hormone agonist trigger and freeze-all strategy does not prevent severe ovarian hyperstimulation syndrome: a report of three cases.
    Gurbuz AS; Gode F; Ozcimen N; Isik AZ
    Reprod Biomed Online; 2014 Nov; 29(5):541-4. PubMed ID: 25246114
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevention of ovarian hyperstimulation syndrome in GnRH agonist IVF cycles in moderate risk patients: randomized study comparing hydroxyethyl starch versus cabergoline and hydroxyethyl starch.
    Matorras R; Andrés M; Mendoza R; Prieto B; Pijoan JI; Expósito A
    Eur J Obstet Gynecol Reprod Biol; 2013 Oct; 170(2):439-43. PubMed ID: 23932181
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rescue in vitro fertilization using a GnRH antagonist in hyper-responders from gonadotropin intrauterine insemination (IUI) cycles.
    Balayla J; Granger L; St-Michel P; Villeneuve M; Fontaine JY; Desrosiers P; Dahdouh EM
    J Assist Reprod Genet; 2013 Jun; 30(6):773-8. PubMed ID: 23715874
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ovarian hyperstimulation syndrome prevention strategies: use of gonadotropin-releasing hormone antagonists.
    Griesinger G
    Semin Reprod Med; 2010 Nov; 28(6):493-9. PubMed ID: 21082508
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparisons of different dosages of gonadotropin-releasing hormone (GnRH) antagonist, short-acting form and single, half-dose, long-acting form of GnRH agonist during controlled ovarian hyperstimulation and in vitro fertilization.
    Hsieh YY; Chang CC; Tsai HD
    Taiwan J Obstet Gynecol; 2008 Mar; 47(1):66-74. PubMed ID: 18400585
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gonadotropin releasing hormone (GnRH) antagonist administration to decrease the risk of ovarian hyperstimulation syndrome in GNRH agonist cycles triggered with human chorionic gonadotropin.
    Mills G; Dahan MH
    Arch Gynecol Obstet; 2022 Nov; 306(5):1731-1737. PubMed ID: 35932297
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Withdrawal of GnRH agonist decreases oestradiol and VEGF concentrations in high responders.
    Ding LJ; Wang B; Shen XY; Yan GJ; Zhang NY; Hu YL; Sun HX
    Reprod Biomed Online; 2013 Aug; 27(2):131-9. PubMed ID: 23764202
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.